Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer

Siegel, 2019, Cancer statistics, 2019, CA A Cancer J. Clin., 69, 7, 10.3322/caac.21551 Torre, 2018, Ovarian cancer statistics, 2018, CA A Cancer J. Clin., 68, 284, 10.3322/caac.21456 Vaughan, 2011, Rethinking ovarian cancer: recommendations for improving outcomes, Nat. Rev. Cancer, 11, 719, 10.1038/nrc3144 Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci. Transl. Med., 5, 10.1126/scitranslmed.3005930 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N. Engl. J. Med., 365, 725, 10.1056/NEJMoa1103849 Pang, 2018, Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy, Mol. Cancer, 17, 91, 10.1186/s12943-018-0840-y Liu, 2018, Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity, Leukemia, 32, 520, 10.1038/leu.2017.226 Morvan, 2016, NK cells and cancer: you can teach innate cells new tricks, Nat. Rev. Cancer, 16, 7, 10.1038/nrc.2015.5 Sutlu, 2012, Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy, Hum. Gene Ther., 23, 1090, 10.1089/hum.2012.080 Suck, 2016, NK-92: an ’off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy, Cancer Immunol. Immunother., 65, 485, 10.1007/s00262-015-1761-x Yu, 2018, Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma, Mol. Ther., 26, 366, 10.1016/j.ymthe.2017.12.012 Ao, 2019, Anti-alphaFR CAR-engineered NK-92 cells display potent cytotoxicity against alphaFR-positive ovarian cancer, J. Immunother., 42, 284, 10.1097/CJI.0000000000000286 Chu, 2014, CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma, Leukemia, 28, 917, 10.1038/leu.2013.279 Hassan, 2016, Mesothelin immunotherapy for cancer: ready for prime time?, J. Clin. Oncol., 34, 4171, 10.1200/JCO.2016.68.3672 H, 1998 Hassan, 2007, Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers, Clin. Cancer Res., 13, 5144, 10.1158/1078-0432.CCR-07-0869 Hassan, 2006, Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer, Clin. Cancer Res., 12, 447, 10.1158/1078-0432.CCR-05-1477 Lanitis, 2012, Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor, Mol. Ther., 20, 633, 10.1038/mt.2011.256 Vivier, 2012, Targeting natural killer cells and natural killer T cells in cancer, Nat. Rev. Immunol., 12, 239, 10.1038/nri3174 Rubnitz, 2010, NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia, J. Clin. Oncol., 28, 955, 10.1200/JCO.2009.24.4590